|
Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer Clinical research trials and Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer. Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer clinical trial. Participants frequently get the best healthcare available for their Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer  Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer
Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer
For Condition: Neoplasm,Cancer
Status: Recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: The purposes of this study are fourfold. It will 1) determine what dose of interleukin-12 (IL-12) and interleukin-2 (IL-2) combination therapy can be given safely to patients with advanced cancer; 2) evaluate the side effects of this treatment; 3) examine how the body handles this drug combination; and 4) determine whether and how the therapy may cause the immune system to stop or slow tumor growth. IL-2 is an approved drug for treating melanoma and kidney cancer. IL-12 is an experimental drug that has shown anti-cancer activity in animals, shrinking tumors and slowing their growth. Animal studies suggest that given together, the drugs may be more effective against cancer than either one singly. Patients 18 years of age and older with advanced solid-tumor cancers (kidney, breast, lung, sarcomas and others) that do not improve with standard treatment may qualify for this study. Candidates will have a physical examination, including blood and urine tests, electrocardiogram (EKG) and echocardiogram, DTH skin test (to test the function of the immune system), chest X-ray and lung function tests to determine eligibility. Bone marrow biopsy and imaging procedures such as CT and MRI scans may also be required. Patients over 50 years old will also undergo exercise stress testing. Treatment will consist of four courses of IL-2 and IL-12. On days one and nine of each course, patients will receive three doses (one every 8 hours) of IL-2 intravenously (through a vein). On days two, four, six, 10, 12 and 14, they will receive IL-12 intravenously. This will be followed by a recovery period from days 15 through 35. This regimen will be repeated for another three cycles; patients who show benefit without severe side effects may continue for additional cycles. Treatment for the first cycle will be administered in the hospital. If the drugs are well tolerated, additional therapy may be given on an outpatient basis. A biopsy (removal of a small sample of tumor tissue) will be done at the beginning of the study, after completing the first treatment cycle, and possibly again when the cancer slows, stops or gets worse, or if the patient leaves the study. These tumor samples will be examined to evaluate the effects of treatment. Several blood samples also will be collected during the course of treatment to monitor immune system effects. A device called a heparin lock may be put in place to avoid multiple needle sticks.
Details: The identification of novel approaches to complement existing modalities utilized to treat patients with cancer remains an important and challenging goal. Interest in the use of various biological agents has been heightened recently by accumulating preclinical and clinical evidence supporting the use of approaches based on tumor vaccines and/or cytokine combinations delivered either systemically or loco-regionally with the use of gene therapy. Recombinant IL-12 is a recently described cytokine, which possesses potent antitumor activity. In animal models, IL-12 has shown significant therapeutic activity, both as a tumor vaccine adjuvant and when it is administered systemically alone or in combination with other cytokines such as interleukin-2. These studies suggest that IL-12 could serve as a useful antitumor agent in humans as well. Although phase I and/or II studies of IL-12 alone have been performed in humans, and IL-2 alone has been approved for use in patients with renal cell carcinoma and melanoma, no trials to evaluate the combination of IL-12 and IL-2 have been performed to date. This phase I dose escalation study will define the maximum tolerated dose and dose-limiting toxicities of IL-12/pulse IL-2, and assess the pharmacokinetics, immunoregulatory, and antitumor effects of this combination administered intravenously to adults with various advanced and/or refractory solid tumors.
Eligibility:
Study Type: Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Adult patients 18 years of age and older. Pathologically or cytologically-proven diagnosis of non-hematologic malignancy, and the presence of radiographically or clinically evaluable disease. Patients with solid tumors including renal, breast, lung carcinomas, as well as sarcomas for whom a proven more effective therapy does not exist. Patients must not have received myelosuppressive chemotherapy, hormonal therapy, radiotherapy or immunotherapy within four weeks of entry onto this protocol. Estimated life expectancy of at least 12 weeks. ECOG performance status of 0 or 1. Patients must be free of acute infection or other significant systemic illness. Negative serologic testing for hepatitis B will be required to limit confounding variables in the assessment of the potential hepatic toxicity of this combination. Negative serologic testing for human immunodeficiency virus (HIV) will be required given the uncertain impact of rhIL-12 and/or rhIL-2 administration on viral replication, and the potential alterations in immune responsiveness among patients concurrently infected with HIV. Adequate hepatic and renal function as evidence by: Transaminases less than 2.5 times the upper limit or normal; Total serum bilirubin less than 2.0 mg/dl; Serum Cr less than 2.0 mg/dl or calculated creatinine clearance of greater than 60 ml/min/1.73M(2). Adequate bone marrow function (without growth factor support) as evidence by: Absolute Neutrophil count (ANC) greater than 1500 cells/mm(3); Platelets greater than 100,000/mm(3). For women of childbearing potential, a negative urine pregnancy test within 14 days prior to initiation of study therapy is required. For patients of child-bearing potential, contraceptive precautions must be maintained during study participation. Normal pulmonary function (as documented by PFTs), and for patients over the age of 50, normal stress thallium testing. Normal pulmonary function testing will be defined as DLCO greater than 60% of predicted and FEVI greater than 70% of predicted. EXCLUSION CRITERIA: Critically-ill or medically unstable patients. History or a presence of brain metastases. History of coronary artery disease, angina or myocardial infarction. Presence of clinically significant pleural effusion. History of malignant hyperthermia are. Concurrent or history of autoimmune disease. History of congenital or acquired coagulation disorder. Patients with a history of ongoing or intermittent bowel obstruction. Women who are pregnant or lactating will be excluded. Systemic corticosteroids, radiotherapy, chemotherapy, or other investigational agents within 4 weeks prior to study entry. Patients who have received any of the following agents with known immunomodulatory effects within 4 weeks prior to study entry: G-CSF/GM-CSF, interferons or interleukins, growth hormone, IVIG, retinoic acid. Patients with a history of previous therapy with rhIL-12 will be excluded from study participation. For patients with renal cell carcinoma, a history of therapy with rhIL-2 will not exclude patients from study participation. Patients with concurrent administration of any other investigational agent. Patients with hematologic malignancies including leukemia or lymphoma. History of bone marrow or stem-cell transplantation. Intercurrent radiation therapy patients will be allowed on study if in the opinion of the principal investigator(s) its use is not necessitated by disease progression. For patients with disease progression, radiation therapy will be administered as clinically indicated and the patient will be withdrawn from study participation.
Total Enrollment: 40
Location and Contact Information:
National Cancer Institute (NCI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Cynthia Donovan 3014028899
Additional Information:
Study ID Numbers: 000121; 00-C-0121
Study Start Date: April 28, 2000
Record last reviewed: March 1, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005655
Other Cancer Studies:
1. Natrecor in Pulmonary Hypertension
2. Screening Patients for NCI Protocol Eligibility
3. Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
4. Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer
5. Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
Related Studies:
Other Cancer Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer
|
|
|
|
|
|
|
|
